Management of Inflammatory Bowel Disease

Stephanie Chandra(1), Marcellus Simadibrata(2),


(1) Department of Internal Medicine, Faculty of Medicine, University of Indonesia Dr. Cipto Mangunkusumo General National Hospital, Jakarta
(2) Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia/Dr. Cipto Mangunkusumo General National Hospital, Jakarta
Corresponding Author

Abstract


Inflammatory bowel disease (IBD) is an inflammatory disease, which involves the digestive tract with still unknown definite etiology. IBD cases are frequently underdiagnosed or even overdiagnosed. Delay in diagnosis often happen due to the unspecific intermittent symptoms. Principally, treatment of IBD is targeted to acute episodes and maintenance of therapy during remission phase. First line therapy drugs include 5-acetil salicylic acid (5-ASA) and corticosteroids are systemic and topical. If failed, then second line therapy, which has immunosuppressive characteristic, is given such as: 6-mercaptopurine, azathioprine, cyclosporine, methotrexate, and anti-TNF (infliximab). Efforts to prevent recurrent inflammation in IBD are to maintain the remission phase as long as possible. Surgery management may be considered if conservative of pharmacological treatment fails or complication happens.

 

Keywords: inflammatory bowel disease, management, treatment


Full Text: FULL TEXT (PDF)

Article Metrics

Abstract View : 704 times
FULL TEXT (PDF) Download : 442 times

DOI: 10.24871/1522014111-114

Refbacks

  • There are currently no refbacks.